RxDoctor Payments Data

Alfred Brannen, MD

Pulmonary Disease · Augusta, GANPI 1902821135

Payments from drug & device makers

$11,718in general payments, 2019–2025

Across 601 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Insmed, Inc.$880
  • Sanofi$628
  • Bayer$610
  • plus $4K from 35 others

What the payments were for

  • Consulting fees$2002%
  • Food & beverage$11,26296%
  • Education$2572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,718 in reported general payments places this provider in the 70th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$217,631
Medicare patients
710
Services billed
2,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter797$849,993
OfevNintedanib Esylate71$793,862
UptraviSelexipag26$698,712
OpsumitMacitentan43$533,546
Breztri AerosphereBudesonide/Glycopyr/Formoterol118$158,638
AdempasRiociguat12$158,253
Breo ElliptaFluticasone/Vilanterol162$106,987
NucalaMepolizumab23$90,106
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr71$55,481
Spiriva RespimatTiotropium Bromide52$54,444
Ambrisentan13$45,322
Tadalafil27$41,943
SymbicortBudesonide/Formoterol Fumarate88$34,145
Albuterol Sulfate HfaAlbuterol Sulfate486$27,296
Fluticasone-SalmeterolFluticasone Propion/Salmeterol108$25,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$1,135$1,232,25869 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$2,066$1,120,7741,077 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$423$889,575180 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,152$192,784206 claims
BayerAdempas$610$158,25312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →